Patents by Inventor Herve ALOYSIUS

Herve ALOYSIUS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide linker and combination for prodrugs activated by prostate-specific antigen
    Patent number: 11628221
    Abstract: The present disclosure is directed to a series of target-selective chemotherapeutic ester prodrugs comprising PSA-cleavable peptides that promote the delivery of free doxorubicin and other chemotherapeutic agents into the prostate and/or prostate tumors with greater efficiency.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: April 18, 2023
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Longqin Hu, Herve Aloysius
  • PEPTIDE LINKER AND COMBINATION FOR PRODRUGS ACTIVATED BY PROSTATE-SPECIFIC ANTIGEN
    Publication number: 20220088209
    Abstract: The present disclosure is directed to a series of target-selective chemotherapeutic ester prodrugs comprising PSA-cleavable peptides that promote the delivery of free doxorubicin and other chemotherapeutic agents into the prostate and/or prostate tumors with greater efficiency.
    Type: Application
    Filed: September 21, 2021
    Publication date: March 24, 2022
    Inventors: Longqin HU, Herve ALOYSIUS
  • Peptide-linked ester prodrugs activated by prostate-specific antigen
    Patent number: 11129901
    Abstract: The present disclosure is directed to a series of target-selective chemotherapeutic ester prodrugs comprising PSA-cleavable peptides that promote the delivery of free doxorubicin and other chemotherapeutic agents into the prostate and/or prostate tumors with greater efficiency.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: September 28, 2021
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Longqin Hu, Herve Aloysius
  • NEW PEPTIDE-LINKED ESTER PRODRUGS ACTIVATED BY PROSTATE-SPECIFIC ANTIGEN
    Publication number: 20190358337
    Abstract: The present disclosure is directed to a series of target-selective chemotherapeutic ester prodrugs comprising PSA-cleavable peptides that promote the delivery of free doxorubicin and other chemotherapeutic agents into the prostate and/or prostate tumors with greater efficiency.
    Type: Application
    Filed: February 2, 2018
    Publication date: November 28, 2019
    Inventors: Longqin HU, Herve ALOYSIUS